ValuEngine upgraded shares of Medicure Inc. (OTCMKTS:MCUJF) from a buy rating to a strong-buy rating in a report issued on Saturday.
Shares of Medicure (OTCMKTS:MCUJF) traded up 11.82% during mid-day trading on Friday, reaching $6.15. 1,300 shares of the company were exchanged. The stock has a market capitalization of $95.73 million, a P/E ratio of 6.49 and a beta of 0.52. Medicure has a 12 month low of $4.11 and a 12 month high of $7.96. The stock has a 50 day moving average price of $5.35 and a 200-day moving average price of $6.60.
Medicure Company Profile
Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).
To view ValuEngine’s full report, visit ValuEngine’s official website.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230777/medicure-inc-mcujf-raised-to-strong-buy-at-valuengine.html
Receive News & Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.